StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM)

Investment analysts at StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

CEL-SCI Stock Down 0.1 %

CVM stock opened at $0.24 on Friday. The company has a 50 day moving average of $0.36 and a two-hundred day moving average of $0.63. The company has a market cap of $19.12 million, a price-to-earnings ratio of -0.50 and a beta of 0.67. CEL-SCI has a 12-month low of $0.23 and a 12-month high of $2.39. The company has a quick ratio of 1.09, a current ratio of 1.07 and a debt-to-equity ratio of 0.66.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CVM. Geode Capital Management LLC lifted its stake in CEL-SCI by 9.6% in the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after acquiring an additional 53,879 shares during the last quarter. Thoroughbred Financial Services LLC increased its position in CEL-SCI by 40.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after buying an additional 54,900 shares during the last quarter. Finally, Plotkin Financial Advisors LLC acquired a new stake in shares of CEL-SCI in the third quarter worth about $98,000. Hedge funds and other institutional investors own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.